Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs BIOAF


Primary Symbol: V.BTI.H

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Boomskidon Jun 21, 2023 11:31am
143 Views
Post# 35507256

Guarantees

Guarantees
Because it's a public company, I expect Biodexa to make an announcement at some point that they acquired some xB3 rights. Otherwise the xB3 Platform will likely disappear into a private company with no announcements to be made until the owners see fit, maybe a couple of years from now. I doubt they would have anything to say until they have IND status on xB3-001 or some other xB3 drug. It’s also possible that xB3 licenses will be sold to other biotechs or pharmas and they could make announcements. 
 
I expect the name “xB3” will disappear. That was my creation, and it’s another in the list of things for which I was not compensated. Bioasis is by far the worst and most costly experience of my life. But if the imaginations of the new owners of xB3 fail, they can call me. I could fire off a dozen other swell names they could use.
 
Zwerp2000 says poof and I will come up with positive things to say about Bioasis. In response I would say that I haven't been positive about Bioasis for two years, but I suppose he can't or won't read anything. There were positive possibilities if xB3 works but those possibilities have now disappeared, I believe.
 
I could have been far more negative about Bioasis but there is a slight problem with that. I must stick with safe harbour types of commentary. I can't state anything for certain that I don't know for certain. If I did speak with certainty then I could face legal challenges. My disclaimers have always made this clear and my writings have always been obvious opinion pieces, never with any guarantees of anything, positive or negative. 
 
I can’t accuse Rathjen of anything, and I haven’t. It will never be possible to prove malice because it requires proof of intent. That is likely impossible unless a Bioasis partner or some other player in these events becomes a whistle blower. I doubt that if there is such a player who harbours relevant information who will ever speak of it.
 
Too many readers (like zwerp2000) of public forums have no idea how to read and understand opinion pieces and the importance of safe harbour statements. I will never make any apologies for trying to do my best, and to offer it all as circumspectly as possible.
 
It would be wise to remember that the market places high value on guarantees. With Bioasis, if there were ever any guarantees, then the market would have priced Bioasis somewhere in the range of Denali’s value, adjusted for relative progress of the two companies and for the market’s assessment of the technologies’ relative capabilities.
 
But Bioasis never did anything with xB3 that could even suggest the possibility of a guarantee. In over 15 years of existence, nothing! Not even close to an IND submission. I said over ten years ago that the lack of such work would be costly. If xB3 works, then it’s truly a special kind of incompetence and failure that Bioasis managements have exhibited. 
 
Well, unless the plan all along was to culture failure, to allow it, or cause it, and to then profit from the failure at the expense of Bioasis shareholders.
 
But we can only express suspicions, opinions, and regrets about any such things. There is one certainty. Bioasis has failed and the shareholders are victims of something, greed and malice, maybe, or simple dumb incompetence. If it was greed and malice then it’s a characteristic of the perpetrator. Such people will always try to beat their partners because life for them is zero sum. They don’t consider anything a win for themselves unless somebody else loses, somebody they’ve beaten. My guess is that the new owners of xB3 will be very suspicious of previous Bioasis management.
 
And, beenthere, you can now call yourself a victim and I will not argue. I now include myself in that list.
 
jd
 
<< Previous
Bullboard Posts
Next >>